Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate

This study has been completed.
National Bank of Austria
Information provided by (Responsible Party):
Martin Niederle, Medical University of Vienna Identifier:
First received: October 15, 2010
Last updated: January 16, 2015
Last verified: January 2015

Patients with primary hyperparathyroidism (pHPT) with osteopenia and osteoporosis are treated with strontium ranelate/Ca+Vitamin-D or placebo/Ca+Vitamin D after successful surgical treatment of pHPT.

Strontium ranelate/Ca + Vitamin-D helps to regain bone mass in patients with osteopenia or osteoporosis after successful parathyroidectomy for pHPT and results in higher gain of BMD than placebo treated patients.

Condition Intervention Phase
Primary Hyperparathyroidism
Drug: Strontium Ranelate + Ca/Vitamin-D
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Bone mineral density measurement of the Lumbar spine [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Bone mineral density of the femoral neck [ Time Frame: 1 year ]
  • Bone mineral density of the radius [ Time Frame: 1 year ]
  • Osteoprotegerin (OPG/OCIF) [ Time Frame: 1 year ]
  • RANKL (OPG-ligand) [ Time Frame: 1 year ]
  • cathepsin K (cat K) [ Time Frame: 1 year ]
  • ionised calcium (Ca++) [ Time Frame: 1 year ]
  • phosphate (PO4-) [ Time Frame: 1 year ]
  • alkaline phosphatase (AP) [ Time Frame: 1 year ]
  • bone-specific alkaline phosphatase (BAP) [ Time Frame: 1 year ]
  • osteocalcin (Oc) [ Time Frame: 1 year ]
  • parathyroid hormone (PTH) [ Time Frame: 1 year ]

Enrollment: 63
Study Start Date: September 2010
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Strontium Ranelate
Receiving Strontium Ranelate + Ca/Vitamin-D
Drug: Strontium Ranelate + Ca/Vitamin-D
2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
Other Name: Protelos (r)
Placebo Comparator: Placebo
Receiving Placebo + Ca/Vitamin D
Drug: Placebo
Placebo 1000mg Calcium 800 IE Vitamin-D

Detailed Description:

The chronic excessive hypersecretion of parathyroid hormone (PTH) has significant impact on bone remodeling. In primary hyperparathyroidism (PHPT) bone turnover is increased, resulting in a higher resorption of bone and thus loss of bone density.

After successful surgical treatment of pHPT bone metabolism switches from catabolic state to anabolic state again. However studies show that especially postmenopausal women regain significantly less BMD but these women suffer from osteopenia and osteoporosis most often and would need to regain as much bone mass as possible to prevent fractures. The optimal state would be to reach normal BMD again. Although this state is hardly reachable especially these patients may benefit from a treatment acting anti-resorptive and rising bone formation. The only drug combining these qualities known so far is Strontium ranelate.

Therefore the hypothesis is that Strontium ranelate/Ca + Vitamin-D helps to regain bone mass in patients with osteopenia or osteoporosis after successful parathyroidectomy for pHPT and results in higher gain of BMD than placebo treated patients.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • biochemically proven PHPT, PTX planned
  • osteopenia (t-score < -1 and > -2.5) or osteoporosis (t-score ≤ -2.5) according to WHO Criteria [27]

Exclusion Criteria:

  • Premenopausal women
  • Cancer (lung, breast, prostatic, parathyroid cancer and thyroid carcinoma >1cm)
  • Persisting or recurrent PHPT (postoperative hypercalcemia)
  • Four-gland hyperplasia
  • Multiple endocrine neoplasia (MEN) or hereditary PHPT
  • Familial hypocalciuric hypercalcaemia (Ca/creatinine ratio < 0.01)
  • Anamnestic pulmonal embolism or deep venous thrombosis
  • Blood coagulation disorder or coagulopathy
  • Phenylketonuria
  • Renal impairment (creatinine clearance <30ml/h)
  • Severe hepatic disorder
  • Severe systemic disorder
  • Thyroid dysfunction
  • Immobilisation
  • Intake of drugs with potential effects on BMD like glucocorticoids, lithium, estrogen-replacement therapy, selective Estrogen-receptor modulators (sERMs), bisphosphonates in the last three months
  • Known allergy against any component of the study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01222026

Medical University Vienna, General Hospital Vienna (AKH Wien)
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
National Bank of Austria
Principal Investigator: Bruno Niederle, Prof., MD Section of Endocrine Surgery, Department of Surgery, Medical University of Vienna
  More Information

Responsible Party: Martin Niederle, MD, PhD, Medical University of Vienna Identifier: NCT01222026     History of Changes
Other Study ID Numbers: EK Nr 214/2008
2008-001703-32 ( EudraCT Number )
Study First Received: October 15, 2010
Last Updated: January 16, 2015

Keywords provided by Medical University of Vienna:
Primary Hyperparathyroidism

Additional relevant MeSH terms:
Hyperparathyroidism, Primary
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Parathyroid Diseases
Endocrine System Diseases
Vitamin D
Strontium ranelate
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on May 22, 2017